Erste Group Bank Brokers Decrease Earnings Estimates for BSX

Boston Scientific Corporation (NYSE:BSX) – Equities research analysts at Erste Group Bank reduced their FY2027 earnings per share (EPS) estimates for Boston Scientific in a research note issued to investors on Wednesday, February 18th. Erste Group Bank analyst H. Engel now anticipates that the medical equipment provider will earn $3.92 per share for the year, down from their previous forecast of $3.94. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share.

BSX has been the subject of several other research reports. Citigroup decreased their price target on Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. TD Cowen decreased their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Robert W. Baird lowered their price target on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a research note on Monday, February 2nd. Finally, BTIG Research reiterated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $108.36.

Boston Scientific Stock Down 1.6%

Shares of NYSE:BSX opened at $74.54 on Monday. The firm has a market cap of $110.61 billion, a P/E ratio of 38.42, a P/E/G ratio of 1.03 and a beta of 0.67. Boston Scientific has a 12-month low of $72.69 and a 12-month high of $109.50. The business has a fifty day simple moving average of $89.23 and a 200 day simple moving average of $96.53. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period last year, the company earned $0.70 EPS. The firm’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS.

Institutional Investors Weigh In On Boston Scientific

Several hedge funds and other institutional investors have recently modified their holdings of the company. Steph & Co. acquired a new stake in Boston Scientific in the 3rd quarter valued at $25,000. Financial Consulate Inc. bought a new position in shares of Boston Scientific in the third quarter valued at $25,000. Murphy & Mullick Capital Management Corp grew its holdings in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the second quarter worth about $26,000. Finally, Swiss RE Ltd. bought a new stake in shares of Boston Scientific during the fourth quarter worth about $26,000. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.